---
layout: default
title: Nebivolol
description: "Nebivolol çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 5 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 112
evidence_level: L5
indication_count: 5
---

# Nebivolol

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>5</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Nebivolol è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Nebivolol å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Nebivolol æ˜¯ä¸€ç¨®å…·æœ‰è¡€ç®¡æ“´å¼µä½œç”¨çš„é«˜é¸æ“‡æ€§ beta-1 é˜»æ–·åŠ‘ï¼ŒTxGNN é æ¸¬å…¶å°æƒ¡æ€§è…è¡€ç®¡æ€§é«˜è¡€å£“å’Œè‚ºé«˜å£“æœ‰æ²»ç™‚æ½›åŠ›ï¼Œé€™äº›é æ¸¬èˆ‡å…¶å·²çŸ¥çš„é™è¡€å£“å’Œå¿ƒè¡€ç®¡ä¿è­·æ©Ÿè½‰å…·æœ‰åˆç†çš„è—¥ç†å­¸é—œè¯ã€‚
</p>


---

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Nebivololï¼ˆè€æ¯”æ´›ï¼‰ |
| DrugBank ID | DB04861 |
| å°ç£å•†å“å | èˆ’çˆ¾è„ˆéŒ ã€è€æ¯”æ´›éŒ ã€æ¬£å€æ³°éŒ  |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | æ²»ç™‚åŸç™¼æ€§é«˜è¡€å£“ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | malignant renovascular hypertensionã€malignant hypertensive renal diseaseã€pulmonary hypertension owing to lung disease and/or hypoxiaã€pulmonary hypertension with unclear multifactorial mechanismã€hypertensive disorder |
| æœ€é«˜é æ¸¬åˆ†æ•¸ | 0.9942ï¼ˆæƒ¡æ€§è…è¡€ç®¡æ€§é«˜è¡€å£“ï¼‰ |
| è­‰æ“šç­‰ç´š | L5ï¼ˆåƒ…é æ¸¬ï¼‰è‡³ L3ï¼ˆæ–‡ç»æ”¯æŒï¼‰ |

---


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. malignant renovascular hypertension</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.42%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

### è—¥ç†æ©Ÿè½‰åˆ†æ

Nebivolol æ˜¯ç¬¬ä¸‰ä»£ beta é˜»æ–·åŠ‘ï¼Œå…·æœ‰ç¨ç‰¹çš„é›™é‡ä½œç”¨æ©Ÿè½‰ï¼š
1. é«˜é¸æ“‡æ€§ beta-1 å—é«”é˜»æ–·
2. é€é L-arginine/ä¸€æ°§åŒ–æ°®é€”å¾‘çš„è¡€ç®¡æ“´å¼µä½œç”¨

å…¶æ©Ÿè½‰èˆ‡é æ¸¬é©æ‡‰ç—‡çš„é—œè¯ï¼š

1. **æƒ¡æ€§è…è¡€ç®¡æ€§é«˜è¡€å£“/æƒ¡æ€§é«˜è¡€å£“æ€§è…ç—…**ï¼ˆTxGNN Score: 0.9942ï¼‰
   - Nebivolol å·²ç²æ ¸å‡†ç”¨æ–¼åŸç™¼æ€§é«˜è¡€å£“
   - å…¶è¡€ç®¡æ“´å¼µä½œç”¨å¯èƒ½åœ¨åš´é‡é«˜è¡€å£“ä¸­æä¾›é¡å¤–ç›Šè™•
   - å°è…è‡Ÿè¡€æµçš„å½±éŸ¿å¯èƒ½å„ªæ–¼å‚³çµ± beta é˜»æ–·åŠ‘
   - **é æ¸¬å…·åˆç†æ€§**ï¼Œä½†éœ€ç¢ºèªåœ¨æƒ¡æ€§é«˜è¡€å£“çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§

2. **è‚ºé«˜å£“ï¼ˆä½æ°§ç›¸é—œï¼‰**ï¼ˆTxGNN Score: 0.9939ï¼‰
   - ä¸€æ°§åŒ–æ°®ä»‹å°çš„è¡€ç®¡æ“´å¼µå¯èƒ½å°è‚ºè¡€ç®¡æœ‰ç›Š
   - å‚³çµ± beta é˜»æ–·åŠ‘åœ¨è‚ºé«˜å£“ä¸­é€šå¸¸ç¦å¿Œæˆ–éœ€è¬¹æ…
   - Nebivolol çš„ç¨ç‰¹æ©Ÿè½‰å¯èƒ½å…‹æœé€™ä¸€é™åˆ¶
   - æ–‡ç»æœ‰ç›¸é—œä½æ°§å’Œè¡€ç®¡èª¿ç¯€çš„ç ”ç©¶

3. **Braddock ç—‡å€™ç¾¤**ï¼ˆTxGNN Score: 0.9914ï¼‰
   - ç½•è¦‹éºå‚³æ€§ç–¾ç—…
   - èˆ‡ Nebivolol æ©Ÿè½‰é—œè¯ä¸æ˜
   - **é æ¸¬åˆç†æ€§è¼ƒä½**

### è‡¨åºŠè©¦é©—

| ç–¾ç—… | è‡¨åºŠè©¦é©—æ•¸é‡ | æœ€é«˜æœŸåˆ¥ | è­‰æ“šç­‰ç´š |
|------|-------------|---------|---------|
| æƒ¡æ€§è…è¡€ç®¡æ€§é«˜è¡€å£“ | 0 | - | L5 |
| è‚ºé«˜å£“ï¼ˆä½æ°§ç›¸é—œï¼‰ | 0 | - | L5 |
| Braddock ç—‡å€™ç¾¤ | 0 | - | L5 |

**çµè«–ï¼šç›®å‰ç„¡é æ¸¬é©æ‡‰ç—‡é€²å…¥è‡¨åºŠè©¦é©—éšæ®µã€‚**

### ç›¸é—œæ–‡ç»

### è‚ºé«˜å£“/ä½æ°§ç›¸é—œæ–‡ç»

| PMID | æ¨™é¡Œ | å¹´ä»½ | é¡å‹ |
|------|------|------|------|
| 33862277 | Hypoxia and brain aging: Neurodegeneration or neuroprotection? | 2021 | ç¶œè¿° |
| 39841808 | Hypoxia as a medicine | 2025 | ç¶œè¿° |
| 28972206 | Regulation of immunity and inflammation by hypoxia | 2017 | ç¶œè¿° |

**æ–‡ç»è©•ä¼°**ï¼š
- ä¸Šè¿°æ–‡ç»ä¸»è¦è¨è«–ä½æ°§å°ç”Ÿç†å’Œç—…ç†çš„å½±éŸ¿
- ä¸¦éç›´æ¥ç ”ç©¶ Nebivolol ç”¨æ–¼è‚ºé«˜å£“
- éœ€è¦æ›´å¤šç›´æ¥è­‰æ“šæ”¯æŒæ­¤é©æ‡‰ç—‡

### Nebivolol çš„ç‰¹æ®Šè—¥ç†ç‰¹æ€§ï¼ˆèƒŒæ™¯çŸ¥è­˜ï¼‰

- Nebivolol é€éåˆºæ¿€å…§çš®ç´°èƒä¸€æ°§åŒ–æ°®åˆé…¶ç”¢ç”Ÿè¡€ç®¡æ“´å¼µ
- æ­¤ç‰¹æ€§ä½¿å…¶èˆ‡å…¶ä»– beta é˜»æ–·åŠ‘ä¸åŒ
- ç†è«–ä¸Šå¯èƒ½åœ¨è‚ºè¡€ç®¡æ“´å¼µæ–¹é¢æœ‰æ½›åŠ›

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. malignant hypertensive renal disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.42%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.42%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. pulmonary hypertension owing to lung disease and/or hypoxia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.39%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.39%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. pulmonary hypertension with unclear multifactorial mechanism</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.39%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.39%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. Braddock syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.14%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.14%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | ç‹€æ…‹ |
|-----------|--------|------|-------------|------|
| è¡›éƒ¨è—¥è£½å­—ç¬¬061041è™Ÿ | èˆ’çˆ¾è„ˆéŒ 5æ¯«å…‹ | éŒ åŠ‘ | ç”Ÿé”åŒ–å­¸è£½è—¥ | æœ‰æ•ˆ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026700è™Ÿ | è€æ¯”æ´›éŒ 5æ¯«å…‹ | éŒ åŠ‘ | ç¾ç´é‡Œå°¼é†«è—¥ | æœ‰æ•ˆ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028953è™Ÿ | æ°Ÿè‰²åŸçƒ·æ´›é¹½é…¸é¹½ï¼ˆåŸæ–™è—¥ï¼‰ | ç²‰åŠ‘ | ç››ä½³åœ‹éš› | æœ‰æ•ˆ |
| è¡›éƒ¨è—¥è£½å­—ç¬¬061020è™Ÿ | æ¬£å€æ³°éŒ 5æ¯«å…‹ | éŒ åŠ‘ | å¥å–¬ä¿¡å…ƒ | æœ‰æ•ˆ |

**å°ç£å…±æœ‰ 4 å¼µç›¸é—œè¨±å¯è­‰ï¼Œå‡ç‚ºæœ‰æ•ˆç‹€æ…‹ã€‚**

---

## å®‰å…¨æ€§è€ƒé‡

### è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰©é¡åˆ¥ | åš´é‡ç¨‹åº¦ | èªªæ˜ |
|-----------------|---------|------|
| Dolasetron | é‡åº¦ï¼ˆMajorï¼‰ | QT å»¶é•·é¢¨éšª |
| å¤šç¨®èƒ°å³¶ç´ è£½åŠ‘ | ä¸­åº¦ï¼ˆModerateï¼‰ | å¯èƒ½æ©è“‹ä½è¡€ç³–ç—‡ç‹€ |
| å£æœé™è¡€ç³–è—¥ | ä¸­åº¦ï¼ˆModerateï¼‰ | å¯èƒ½æ©è“‹ä½è¡€ç³–ç—‡ç‹€ |
| è…ä¸Šè…ºç´  | ä¸­åº¦ï¼ˆModerateï¼‰ | å¯èƒ½å¢å¼·è¡€å£“æ•ˆæ‡‰ |
| çš®è³ªé¡å›ºé†‡ | ä¸­åº¦ï¼ˆModerateï¼‰ | å¯èƒ½é™ä½é™å£“æ•ˆæœ |
| éˆ£è£œå……åŠ‘ | ä¸­åº¦ï¼ˆModerateï¼‰ | å¯èƒ½å½±éŸ¿å¿ƒè‡Ÿå‚³å° |
| æŠ—è†½é¹¼è—¥ç‰© | ä¸­åº¦ï¼ˆModerateï¼‰ | å¯èƒ½å½±éŸ¿å¿ƒè·³ |

### ä¸»è¦è­¦å‘Š

1. **å‘¼å¸ç³»çµ±**
   - æ”¯æ°£ç®¡ç—™æ”£æ‚£è€…éœ€è¬¹æ…
   - ç›¸è¼ƒéé¸æ“‡æ€§ beta é˜»æ–·åŠ‘é¢¨éšªè¼ƒä½

2. **å¿ƒè¡€ç®¡ç³»çµ±**
   - åš´é‡å¿ƒè·³éæ…¢ç¦ç”¨
   - å¿ƒè‡Ÿå‚³å°éšœç¤™éœ€è¬¹æ…

3. **ä»£è¬å½±éŸ¿**
   - ç³–å°¿ç—…æ‚£è€…éœ€ç›£æ¸¬è¡€ç³–
   - å¯èƒ½æ©è“‹ä½è¡€ç³–ç—‡ç‹€

4. **çªç„¶åœè—¥**
   - å¯èƒ½å°è‡´åè·³æ€§é«˜è¡€å£“
   - éœ€é€æ¼¸æ¸›é‡

---

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šMany psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially duri...
- å»ºè­°ï¼šCaution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihype...



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Cerebrovascular Disorders** ğŸŸ¡ Moderate
- Beta-adrenergic blocking agents (beta-blockers), should be used with caution in patients with cerebrovascular insufficiency because of their potential effects relative to blood pressure and pulse.  If signs or symptoms suggesting reduced cerebral blo...

**é’å…‰çœ¼ (Glaucoma)** ğŸŸ¡ Moderate
- Systemic beta-adrenergic receptor blocking agents (aka beta-blockers) may lower intraocular pressure.  Therefore, patients with glaucoma or intraocular hypertension may require adjustments in their ophthalmic regimen following a dosing change or disc...

**Hyperlipidemias** ğŸŸ¡ Moderate
- Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles.  Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers.  Patient...

**ç”²ç‹€è…ºæ©Ÿèƒ½äº¢é€² (Hyperthyroidism)** ğŸŸ¡ Moderate
- When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid st...

**é‡ç—‡è‚Œç„¡åŠ› (Myasthenia Gravis)** ğŸŸ¡ Moderate
- Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggrav...

*å¦æœ‰ 13 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### è©•ä¼°çµè«–

| é æ¸¬é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | è‡¨åºŠè½‰è­¯å¯è¡Œæ€§ | å»ºè­°å„ªå…ˆé †åº |
|-----------|---------|---------------|-------------|
| æƒ¡æ€§è…è¡€ç®¡æ€§é«˜è¡€å£“ | L5 | ä¸­ç­‰ | å¯è€ƒæ…®é€²ä¸€æ­¥ç ”ç©¶ |
| è‚ºé«˜å£“ï¼ˆä½æ°§ç›¸é—œï¼‰ | L5 | ä¸­ç­‰ | éœ€è¬¹æ…è©•ä¼° |
| Braddock ç—‡å€™ç¾¤ | L5 | ä½ | ä¸å»ºè­°é–‹ç™¼ |

### å»ºè­°

1. **æƒ¡æ€§è…è¡€ç®¡æ€§é«˜è¡€å£“**
   - Nebivolol å·²ç”¨æ–¼é«˜è¡€å£“æ²»ç™‚
   - å…¶ç¨ç‰¹çš„è¡€ç®¡æ“´å¼µæ©Ÿè½‰å¯èƒ½åœ¨åš´é‡é«˜è¡€å£“ä¸­æœ‰å„ªå‹¢
   - **å»ºè­°**ï¼šå¯è€ƒæ…®å›é¡§æ€§åˆ†æç¾æœ‰é«˜è¡€å£“è‡¨åºŠè©¦é©—ä¸­æƒ¡æ€§é«˜è¡€å£“äºçµ„çš„ç™‚æ•ˆ

2. **è‚ºé«˜å£“ï¼ˆä½æ°§ç›¸é—œï¼‰**
   - ä¸€æ°§åŒ–æ°®ä»‹å°çš„è¡€ç®¡æ“´å¼µæ©Ÿè½‰å…·æœ‰ç†è«–åŸºç¤
   - ä½†å‚³çµ± beta é˜»æ–·åŠ‘åœ¨è‚ºé«˜å£“ä¸­éœ€è¬¹æ…
   - **å»ºè­°**ï¼šéœ€é€²è¡Œå°è¦æ¨¡å‰ç»æ€§ç ”ç©¶è©•ä¼°å®‰å…¨æ€§

3. **æ•´é«”è©•ä¼°**
   - Nebivolol çš„ç¨ç‰¹è—¥ç†ç‰¹æ€§ä½¿å…¶æˆç‚ºå€¼å¾—é—œæ³¨çš„è€è—¥æ–°ç”¨å€™é¸
   - ä½†ç›®å‰è­‰æ“šä¸è¶³ä»¥æ”¯æŒç›´æ¥è‡¨åºŠé–‹ç™¼

### å¾ŒçºŒè¡Œå‹•

- [ ] æ–‡ç»æª¢ç´¢ï¼šNebivolol åœ¨åš´é‡/é›£æ²»æ€§é«˜è¡€å£“ä¸­çš„ç™‚æ•ˆå ±å‘Š
- [ ] è©•ä¼°æ˜¯å¦æœ‰è‚ºé«˜å£“å‹•ç‰©æ¨¡å‹ç ”ç©¶
- [ ] ç›£æ¸¬ç›¸é—œè‡¨åºŠè©¦é©—çš„å•Ÿå‹•

---

*å ±å‘Šç”¢ç”Ÿæ—¥æœŸï¼š2026-02-11*
*è³‡æ–™ä¾†æºï¼šTxGNN é æ¸¬ã€ClinicalTrials.govã€PubMedã€å°ç£ FDA*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Trifluoperazine]({{ "/drugs/trifluoperazine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Caplacizumab]({{ "/drugs/caplacizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Treprostinil]({{ "/drugs/treprostinil/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Benazepril]({{ "/drugs/benazepril/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tolmetin]({{ "/drugs/tolmetin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Nebivololè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/nebivolol/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_nebivolol,
  title = {Nebivololè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/nebivolol/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
